FLIR Systems, Inc. (NASDAQ:FLIR) Anticipation of tomorrow's Federal Reserve open market meeting is building, and the indication from investors thus far, following a second straight day of big gains in the broad-based S&P 500 , is that they expect the ...

Regeneron Pharmaceuticals, Inc. Presents at Goldman Sachs 34th Annual Global Healthcare Conference, Jun-11-2013 08:40 AM.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) should spike� every time there's a slight pullback the stock shoots higher.

Fellow major biotech stock Regeneron Pharmaceuticals Inc (NASDAQ:REGN) lost 5% during the week, part of a sustained 15% slump over the past month.

Sanofi SA (ADR) (NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) are developing dupilumab to cure moderate to severe allergic asthma.

(By Mani) Eylea is the main profit and growth driver for Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). Eylea is used to treat age-related wet macular degeneration (AMD), a condition that affects a tiny part of the retina at the back of the eye.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) a biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally is ...

TARRYTOWN, N.Y., June 06, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare today announced positive top-line results for EYLEA(�) (aflibercept) Injection from the Phase 3 MYRROR study in myopic ...

Regeneron Pharmaceuticals, Inc. (REGN) Presents at 38th Annual Deutsche Bank Health Care Conference May 29, 2013 8:40 AM ET.

Murray A. Goldberg - Chief Financial Officer, Senior Vice President of Finance & Administration and Assistant Secretary. Analysts.